Part IV: Genetic variations in β2-adrenergic receptors: Long-acting and short-acting β2-agonists and therapeutic response

Current Medical Research and Opinion

Volumn 23, Issue SUPPL. 3, 2007, Pages

  Peters, Stephen ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

2 Adrenergic receptors; Arg Arg genotype; Genetic polymorphism; Long acting 2 agonists; Short acting 2 agonists; Therapeutic response

Indexed keywords

ARGININE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FENOTEROL; FORMOTEROL; GLYCINE; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG;

CHILD CARE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE INDUCED ASTHMA; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOW DRUG DOSE; MORTALITY; NOCTURNAL ASTHMA; PEAK EXPIRATORY FLOW; PHENOTYPE; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; AMINO ACID SUBSTITUTION; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2;

EID: 35648954123     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907     Document Type: Review

References (33)

1. Kelly HW. What is new with the beta2-agonists: issues in the management of asthma Ann Pharmacother 2005;39:931-8
2. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996;335:841-7
3. Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000;355:1675-9
4. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6
5. Taylor DR, Herbison GP, Sears MR. Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline. Thorax 1993;48:776
6. Taylor DR, Town GI, Herbison GP, et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998;53:744-52
7. Israel E, Chinchilli VM, Ford JG, et al, for the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364:1505-12
8. Santillan AA, Camargo CA Jr, Ramirez-Rivera A, et al. Association between beta2-adrenoceptor polymorphisms and asthma diagnosis among Mexican adults. J Allergy Clin Immunol 2003;112:1095-100
9. Anderson GP. Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation. Am J Respir Crit Care Med 2000;161(3 Pt 2):S188-96
10. Thakkinstian A, McEvoy M, Minelli C, et al. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 2005;162:201-11
11. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Nad Acad Sci USA 2000;97:10483-8
12. Hawkins GA, Tantisira K, Meyers DA, et al. Sequence, haplotype and association analysis of ADRβ2 in multi-ethnic asthma case/control subjects. Am J Respir Crit Care Med 2006;174:1101-9
13. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003;43:381-411
14. Litonjua AA. The significance of beta2-adrenergic receptor polymorphisms in asthma. Curr Opin Pulm Med 2006;12:12-17
15. Tattersfield AE, Hall IP. Are beta2-adrenoceptor polymorphisms important in asthma - an unravelling story. Lancet 2004;364:1464-6
16. D'amato M, Vitiani LR, Petrelli G, et al. Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (ADRB2) haplotypes. A population study Am J Respir Crit Care Med 1998;158:1968-73
17. Hall IP, Wheatley A, Wilding P, Liggett SB. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995;345:1213-4
18. Tan S, Hall IP, Dewar J, et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997;350:995-9
19. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997;100:3184-8
20. 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999;65:519-25
21. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000;162:75-80
22. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000;55:762-7
23. Israel E, Chinchilli VM, Ford JG, et al, for the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet 2004;364:1505-12
24. Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-203
25. Cloosterman SG, Bijl-Hofland ID, van Herwaarden CL, et al. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients. Chest 2001;119:1306-15
26. FitzGerald JM, Chapman KR, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. J Allergy Clin Immunol 1999;103(3 Pt 1):427-35
27. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
28. 2 adrenergic receptor polymorphism associates with markers of asthma severity in African Americans. J Asthma 2006;43:185-91
29. FDA Public Health Advisory: Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). Created November 18, 2005; Updated May 15, 2006. Available at: http://www.fda.gov/cder/drug/advisory/LABA.htm [Last accessed 26 January 2007]
30. FDA Pulmonary-Allergy Drugs Advisory Committee Meeting Briefing Document. Safety of long-acting beta-agonist bronchodilators. July 13, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005_4148B1_01_01-GSK- Serevent.pdf [Last accessed 23 January 2007]
31. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7
32. 2- adrenoceptor genotype predisposes to exacerbations in young asthmatcs taking regular salmeterol. Thorax 2006;61:940-4
33. National Asthma Education and Prevention Program. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics - 2002. J Allergy Clin Immunol 2002;110(5 Suppl):S141-219